PHARMACY

Kmart garners top ranking on pharmacy customer satisfaction index

BY Brian Berk

ANN ARBOR, Mich. — Kmart earned the top ranking — a score of 84 out of a possible 100 — in the health and wellness/pharmacy category in the recently released American Customer Satisfaction Index “Retail Report 2016.” Kmart’s ranking rose from a score of 76 the prior year, good for a 10.5% year-over-year increase.

Alberstons placed second on the list with a score of 83, followed by “all others” at 82, Kroger at 81, Target at 79, Rite Aid at 78, and CVS, Walgreens and Walmart all finishing with a score of 76. Of note, Albertsons, Rite Aid, CVS, Walgreens and Walmart all saw significant rises in year-over-year customer satisfaction, with all advancing at least 3%.

Overall, customer satisfaction in this category rose 6.8% year over year to an ACSI score of 78. Customers were especially happy with locations and operating hours of health and personal care stores, scoring an 86 in this category, beating out other retail categories.

The quality of pharmacy services also saw a strong rise in 2016, rising 4% to a score of 84. “According to customers, staff are more courteous and helpful than they were a year ago, and the checkout process, is faster (both up 5% to 83 and 79, respectively),” ACSI noted in its report. “Customers crave more sales and promotions as they still rate the feature at the low end, although there is slight improvement (up 1% to 76).

To compile its statistics, Ann Arbor-based ACSI uses data from interviews with roughly 70,000 customers annually as inputs to an econometric model for analyzing customer satisfaction with more than 300 companies in 43 industries and 10 economic sectors.

For more information about the report, click here.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

NCPA calls for Congressional hearings on DIR practice

BY Michael Johnsen

ALEXANDRIA, Va. – The National Community Pharmacists Association on Friday requested Congressional hearings on legislation, the Improving Transparency and Accuracy in Medicare Part D Spending Act (S. 413 and H.R. 1038), that would stop the practice of pharmacy direct and indirect remuneration fees being applied retroactively under Medicare Part D.

“Retroactive pharmacy DIR fees are creating a system of winners and losers,” stated Douglas Hoey, NCPA CEO. “While pharmacy benefit managers profit, the unpredictable timing and amount of these clawbacks are wreaking financial havoc on pharmacies, seniors and taxpayers," he said.

"NCPA believes these congressional committees should schedule hearings soon on S. 413 and H.R. 1038 to address this unsustainable situation," Hoey added. "By requiring PBMs to divulge the costs of prescription drugs for Medicare beneficiaries at the point of sale, these bills fix a problem even the Centers for Medicare & Medicaid Services acknowledges has contributed to rising costs in Medicare Part D. A hearing provides the platform for the scrutiny this issue deserves.”

The request was made from NCPA to the chair and ranking member of the Senate Finance Committee and to the chair and ranking members of the House Energy and Commerce Committee and the House Ways & Means Committee, the committees with jurisdiction over this issue.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Mylan introduces Pristiq generic

BY Brian Berk

PITTSBURGH — Mylan introduced Desvenlafaxine Extended-release Tablets, 50 mg and 100 mg, a generic version of Pfizer's Pristiq Tablets, in the United States.

Desvenlafaxine is indicated for the treatment of a major depressive disorder. Desvenlafaxine Extended-release Tablets, 50 mg and 100 mg, had U.S. sales of approximately $853 million for the 12 months ending January 31, 2017, according to IMS Health.

As Drug Store News reported, Teva Pharmaceuticals also launched a generic version of Pristiq on March 1.

 Mylan offers a portfolio of approximately 7,500 marketed products around the world, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES